American College of Rheumatology Convergence (ACR)

November 25, 2022

Results indicated that vaccine response with the standard regimen dramatically low; however, both novel strategies were able to significantly improve response.

November 24, 2022

“These are people with autoimmune conditions who are taking immunomodulatory drugs that affect their immune system,” Mudano emphasized. “It's been shown that they may have worse outcomes if they do get COVID. So, it's important that they know that they really need this vaccine.”

November 23, 2022

Although the ACR and EULAR have introduced guidelines for initial treatment of Takayasu Arteritis, Robert Maughan, PhD, explains that there is little to no data available to guide decisions.

November 15, 2022

Deepak Bhatt, MD, MPH, discusses a posthoc analysis of the ORAL Surveillance trial examining drivers of increased cardiovascular risk observed in the phase 3b/4 trial in patients with rheumatoid arthritis.

November 14, 2022

ASAS40 responses increased between week 16 and week 52 in patients with non-radiographic axial spondyloarthritis and ankylosing spondylitis.

November 14, 2022

A trial comparing a 1-week methotrexate hold following seasonal influenza vaccination against the standard 2-week hold among patients with rheumatoid arthritis using methotrexate suggests there were no significant differences in positive vaccine response with either approach.

November 13, 2022

ABP 501 is an adalimumab biosimilar that was recently approved the European Medicines Agency.

November 13, 2022

Investigators used interviews, performed in a patient’s preferred language and transcribed verbatim, to better uncover and understand what matters most to the Hispanic population.

November 13, 2022

A systematic review and meta-analysis presented at ACR Convergence 22 provide insight into the effects of belimumab in patient populations with cutaneous lupus erythematosus, with or without systemic lupus erythematosus.

November 13, 2022

There was also a reduction in ultrasound features of gout at the knee identified, with improvement found in 63% of the tight control group and 14% of the conventional group.